Frova (frovatriptan succinate) first for female migraine sufferers

FROVA® is generally well tolerated

Adverse events profile similar to that of placebo in clinical trials
  • In a preclinical study FROVA produced selective constriction of the carotid vascular bed and no effect on blood pressure or coronary resistance1
  • In isolated human arteries (ex vivo) FROVA was more selective for cerebral vessels than coronary vessels2

aIncidence >2% and greater than placebo among patients in 4 placebo-controlled trials.

Maria, 23 has concerns about the side effects of prescription migraine medications
Important Safety Information additonal Vermont prescriber information is available
FR-0270-01/June 2008